

III INTERNATIONAL LUNG CANCER DEBATES 2025 January 31st & February 1st, 2025, Canary Islands

SCIENTIFIC COORDINATORS

Dr. Rosario García Campello, Complejo Hospitalario Universitario de A Coruña

Dr. Luis Paz-Ares. Hospital Universitario 12 de Octubre. Madrid

Dr. Delvys Rodríguez Abreu. Hospital Universitario Insular, Las Palmas de Gran Canaria

Friday 31st January

09:00-09:15 Welcome and official opening

Dr. Rosario García Campello, Complejo Hospitalario Universitario de A Coruña

Dr. Luis Paz-Ares. Hospital Universitario 12 de Octubre. Madrid

Dr. Delvys Rodríguez Abreu. Hospital Universitario Insular, Las Palmas de Gran Canaria

09:15-09:35 Lecture: EGFR from the biology to future?

Dr. Passi Jane. Dana Farber. Boston. USA

09:45-10:55 SESSION I. EGFR NSCLC

Chairs:

Dra. Pilar Garrido. Madrid

Dra. Enriqueta Felip

Early stage: neoadjuvant and adjuvant

09:45-10:00 Adjuvant therapy. Time? Chemo or Not? Combinations?

Dr. Majem

10:00-10:15 Are we ready for neoadjuvant therapy in EGFR or better consolidation.

Dr. Jon Zubizagoitia

Advanced stage 1st line

10:15-10:30 How to decide which patients need combination approaches.

Dra. Anne-Marie Dingemans

10:30-10:45 How to decide which patients can receive mono?

Dr. Federico Cappuzzo

10:45-10:55 Panel Discussion—

10:55- 11:25 COFFEE BREAK

11:25-12:25 SESSION I. EGFR NSCLC. Advanced stage later lines

11:25-11:40 Biomarker select treatment.?

Dr. TBD Besse

11:40-11:55 Non biomarker select treatment?

Dr. TBD Hendriks

11:55-12:10 New ADCs and Bi-specifics antibodies

Dr. TBD M Reck

12:10-12:25 Panel Discussion

12:25-12:35 Exon 20 insertions. Not so uncommon disease but different treatments?

Dr. Antonio Passaro

12:35-12:45 Others uncommon EGFR mutations. Treatment options?

Dr. Remon

12:45-12:55 HER2 deregulated NSCLC. ADC or TKIs treatment?

Dra. Lorenza Landi

12:55 – 14:00 Panel Discussion: All the authors— Antonio Calles

14:00- 15:05 LUNCH BREAK

15:05-16:20 SESSION 2. Metastatic NSCLC others mutations

Chairs:

Dr. Bartomeu Massuti. Hospital Universitario Dr. Balmis, Alicante, Spain

Dr. Javier de Castro. Hospital La Paz. Madrid. Spain

15:05-15:20 ALK positive NSCLC. What else in the kingdom of Lorlatinib?

Dr. Ross Camidge

15:20-15:35 News in the ROS1 and RET world.

Dr. Borghaei

15:35-15:50 NTRK and MET. How should we treat these rare alterations?

Dr. Drilon

15:50-16:05 BRAF mutant NSCLC. First TKI or CT/IO

Dr. David Planchard, Institut Gustave Roussy, Paris, France

16:05-16:20 Panel Discussion— Luis Raez

16:20-17:20 SESSION 3. KRAS NSCLC

Chairs: Dra. Isla, Dr. Paz Ares

16:20-16:35 KRAS G12C. Monotherapy

Dra. Natasha Leigh

16:35-16:50 KRAS G12C. Combination approaches

Dr. Jarushka Naidoo. Beaumont RCSI Cancer Centre, Dublin (Ireland)

16:50-17:05 KRAS non G12C. What do we have for them?

Dr. Santiago Ponce

17:05- 17:20 The new targets in NSCLC. NRG1, Pi3K, others

Dr. Rolfo

17:20- 17:35 Panel Discussion—

17:35-17:50 COFFEE BREAK

17:50-18:30 SESSION 4. Small cell carcinoma

Chairs: Dra. Noemi Reguart. Hospital Clinic Barcelona

Dr. Stahel

17:50-18:05 What are the true implication of SCLC biology in the clinical practice.

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington (USA)

18:05-18:20 New drugs in SCLC

Dr. Rudin

18.20-18:35 Discussion and Q&A

18:35 CLOSING

Saturday 1st February

09:45- 12:30 SESSION 5—IMMUNOTHERAPY IN NSCLC

Chairs: Dr. Mariano Provencio. Hospital Universitario Puerta del Hierro, Madrid

Dr. Spicer

09:45-10:00 In which patients the neoadjuvant IO is enough?

Dr. Tina Cascone

10:00-10:15 Which patient need more after Neo and how personalize it?

Dr.

10:15-10:30 Best treatment option during and after radiotherapy in E-III?

Dr. Sanjay Popat. The Royal Marsden. London. UK

10:30-10:45 Discussion and Q&A

10:45-10:50 Should we abandon the TIGIT pathway definitely?

Dr. Baar

10:50- 11. 00 Will be the anti PD1/L1 plus ADCs the new standard in 1L?

Dr. Marina Garassino. University of Chicago. USA

11:00- 11:15 COFFEE BREAK

11:15-11. 25 Next generation of immune checkpoints

Dr. Solange Peters. Centre Hospitalier Universitaire Vaudois (CHUV). Lausanne. Switzerland

11:25-11. 35 Agnostic ADCs in second line?

Dr. TBD

11:35- 11. 45 Bispecific ADCs targeting dual immune checkpoints and others

Dr. William William

11:35- 11. 45 How far are we from cellular therapy and vaccine in lung cancer?

Dr. Creelan

11.45-12.00 Artificial intelligence in LC from research to clinic: How and When?

Dra. Marcela Prelaj

12:00- 12:20 CLOSING REMARKS
